General Discussion Topics, page-97

The TEVA deal was briefly great at the time, but Mayne Pharma shorter's got dug in like Alabama ticks as other companies involved in the divesture began to realize they'd drunk from a poisoned chalice. The shorter's were right and Mayne followed the same downward trend as their peers.

Now putting the TEVA deal aside; Mayne's new promises haven't been met and Mayne still languishes. Expect more 'cost saving' restructures and write-offs this year.

Turn around only begins with serious earnings, the only apparent catalyst being Nextstellis, which i'm not sure will even be made in one of their two factories??

In fact, what is being made in their own facilities, that is making a strong contribution to the business? or are most of the good products licensed, imported and distributed? If they are not manufacturing alot, do they need multiple sites??